MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature

MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature

Abstract Background Antibodies to human full-length myelin oligodendrocyte glycoprotein (MOG-IgG) as detected by new-generation cell-based assays have recently been described in patients presenting with acute demyelinating disease of the central nervous system, including patients previously diagnose...

Full description

Bibliographic Details
Main Authors: S. Jarius, K. Ruprecht, J. P. Stellmann, A. Huss, I. Ayzenberg, A. Willing, C. Trebst, M. Pawlitzki, A. Abdelhak, T. Grüter, F. Leypoldt, J. Haas, I. Kleiter, H. Tumani, K. Fechner, M. Reindl, F. Paul, B. Wildemann
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Journal of Neuroinflammation
Subjects:
Myelin oligodendrocyte glycoprotein (MOG)
Antibodies
Immunoglobulin G
MOG-IgG
Primary chronic progressive MS (PPMS)
Secondary chronic progressive MS (SPMS)
Online Access:http://link.springer.com/article/10.1186/s12974-018-1108-6

Internet

http://link.springer.com/article/10.1186/s12974-018-1108-6

Similar Items